,
“Using electronic health record data for substance use Screening, Brief Intervention, and Referral to Treatment among adults with type 2 diabetes: Design of a National Drug Abuse Treatment Clinical Trials Network study.”, Contemp Clin Trials, vol. 46, pp. 30-38, 2016.
, “Testing and linkage to HIV care in China: a cluster-randomised trial.”, Lancet HIV, vol. 4, no. 12, pp. e555-e565, 2017.
, “DSM-5 substance use disorders among adult primary care patients: Results from a multisite study.”, Drug Alcohol Depend, vol. 179, pp. 42-46, 2017.
, “Design of the Buprenorphine Physician-Pharmacist Collaborative Care of Patients with Opioid Use Disorder. ”, in 81st Annual Scientific Meeting of the College of Problems on Drug Disorders (CPDD), , San Antonio, TX. , 2019.
, ,
“Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial.”, Neurology, vol. 63, no. 9, pp. 1705-7, 2004.
, “Impact of Antioxidants, Zinc, and Copper on Cognition in the Elderly: A Randomized, Controlled Trial”, Neurology, vol. 63, pp. 1705-1707, 2004.
, “Genome-wide analysis of disease progression in age-related macular degeneration.”, Hum Mol Genet, vol. 27, no. 5, pp. 929-940, 2018.
, “Induction of human T-Cell-Mediated immune responses after primary and secondary smallpox vaccination”, J Infectious Diseases, vol. 190, pp. 1286-94, 2004.
, “Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: BMT CTN Protocol”, Biol Blood Marrow Transplant, vol. 20, pp. 858-864, 2014.
, “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
, “Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning”, Nature Medicine, vol. 9, pp. 416-423, 2003.
, “Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.”, Nat Med, vol. 9, no. 4, pp. 416-23, 2003.
, “Operational Data Management within the Clinical Trials Network of the National Institute on Drug Abuse (NIDA CTN)”, in 20th Annual Conference of the Society for Clinical Data Management, Las Vegas, NV, 2014.
, “Monitoring Medication Adherence Electronically: Considerations and a Case Study”, in Society for Clinical Trials 35th Annual Meeting, Philadelphia, PA, 2014.
, “Optimizing an Existing Data Collection System for Tablet Compatibility: Considerations and a Case Study”, in Society for Clinical Trials 35th Annual Meeting, Philadelphia, PA, 2014.
, “Conception by fertility treatment and offspring deoxyribonucleic acid methylation.”, Fertil Steril, vol. 116, no. 2, pp. 493-504, 2021.
, “Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.”, Biol Blood Marrow Transplant, vol. 22, no. 2, pp. 359-370, 2016.
, “Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.”, Ophthalmology, vol. 126, no. 2, pp. 261-273, 2019.
, “Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.”, Blood, vol. 129, no. 2, pp. 162-170, 2017.
, “Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.”, J Infect Dis, vol. 197, no. 4, pp. 580-3, 2008.
, “Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans”, J Infec Dis, vol. 197, pp. 580-583, 2008.
, “Early-Phase Clinical Trials in the Community: Results from the National Cancer Institute Community Cancer Centers Program Early-Phase Working Group Baseline Assessment”, J Oncol Pract, vol. 9, pp. e55-e61, 2013.
, “Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.”, J Oncol Pract, vol. 9, no. 2, pp. e55-61, 2013.
,